A first-in-class, Phase 2 novel and critical driver of advancing science in treating the condition of Acute Respiratory Distress Syndrome (ARDS), with a mortality rate reaching upwards of 40%, and without approved therapeutics. This program has the potential to fundamentally change the treatment paradigm for a condition with staggering unmet medical need and mortality. The primary molecule initiates and perpetuates the uncontrolled inflammation and vascular lung injury characteristic of ARDS and is validated by robust preclinical data across multiple relevant small and large animal models and supported by human translational studies. The program has successfully completed a 32-subject Phase 1a study in healthy volunteers, demonstrating an excellent safety and tolerability profile with zero serious adverse events. The program has also been evaluated in a Phase 2a study in moderate/severe ARDS patients. Initial data from the first patient cohort of 15 patients is highly encouraging, showing the absence of serious drug-related adverse events and a pharmacokinetic profile consistent with Phase 1 results. With a breakthrough therapy designation, a validated target, a clear biomarker strategy, and a de-risked clinical profile, this candidate represents a compelling, high-impact investment opportunity in a major market with no effective pharmacological treatments.